According to filings with the Securities and Exchange Commission (SEC) on May 26, 2026, detailing activity from May 21, 2026, Gaurav Shah, CEO of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), disclosed recent transactions involving the company's common stock. The filings provided a detailed view of both sales and acquisitions by executive leadership.
Specifically, Mr. Shah executed a sale of 55,684 shares of the company’s common stock. This divestiture totaled approximately $171,840. The proceeds were realized through multiple transactions, with individual share prices ranging from $3.08 to $3.105. The stated purpose for this sale was to cover both the exercise price and associated taxes linked to a stock option.
The reported sales followed a substantial acquisition by Mr. Shah. Prior to the recent divestiture, he had acquired 76,490 shares of common stock through the exercise of a stock option. This purchase was valued at approximately $129,344, based on an exercise price of $1.691 per share. These newly acquired shares were received before the expiration date of April 12, 2027.
The details surrounding the original stock option included a total grant of 76,490 shares. The vesting schedule was structured such that one-third vested on April 12, 2018, and the remaining two-thirds were set to vest in equal quarterly increments over the subsequent two years.
Following these disclosed transactions, Mr. Shah currently holds a direct ownership stake of 1,061,724 shares of Rocket Pharmaceuticals common stock. At the time of reporting, RCKT stock was trading at $2.99, representing a decline of 52% over the preceding year. Further context provided by InvestingPro analysis suggests that the stock may be undervalued at current levels, noting the company's market capitalization of $328 million. This valuation estimate includes Restricted Stock Units (RSUs) that are convertible to common stock on a one-for-one basis.
In addition to his direct holdings, Mr. Shah maintains indirect ownership through related entities. These include 207,897 shares held via his spouse and an additional 198,341 shares managed through the Gaurav D. Shah Irrevocable Trust.
Strategic Corporate Developments
Beyond insider activity, Rocket Pharmaceuticals has been involved in several significant corporate developments that are drawing market attention. Most notably, the company successfully sold its Rare Pediatric Disease Priority Review Voucher for $180 million. This voucher sale was executed after the FDA granted accelerated approval of Kresladi. The proceeds from this transaction are expected to extend the company’s cash runway into the second quarter of 2028.
Furthermore, Rocket Pharmaceuticals convened its 2026 Annual Meeting of Stockholders. During this meeting, shareholders formally approved the election of seven directors to serve on the board. These corporate activities underscore the firm's ongoing strategic initiatives and market positioning.
Analyst Response and Price Targets
The company’s recent progress has prompted several financial analysts to revise their price targets for Rocket Pharmaceuticals. Leerink Partners, for instance, increased its price target to $12.00, citing the value derived from the voucher sale. Separately, BofA Securities raised its target to $9.00 while maintaining a Buy rating.
It is also noted that Leerink Partners had previously elevated its target to $11.00 following the FDA's approval of Kresladi for leukocyte adhesion deficiency-I. These updates and analyses provide insight into how external market observers are reacting to the company’s operational milestones and financial strength.
Market Context
The most recent trading data shows that RCKT was quoted at $2.99, with a slight increase of 0.03 (1.01%) in its after-hours session, closing at 15:59:59 USD.